Trial Profile

Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) Who Completed Study ARGX-113-2104

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 09 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Dec 2024 Status changed from active, no longer recruiting to discontinued. (Due to the phase 2 results (ARGX-113-2105) showing that efgartigimod-treated PC-POTS patients had no clinically meaningful improvement the decision has been made to terminate the ongoing ARGX-113-2105 study. )
14 May 2024 Planned End Date changed from 1 May 2025 to 7 May 2025.
14 May 2024 Planned primary completion date changed from 1 May 2025 to 7 May 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com